

29A 3485

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MASARU MURASHITA

Serial No: 10/691,070

Filed: October 22, 2003

For: ULTRASONIC DIAGNOSTIC
APPARATUS

Art Unit: 3737

Examiner: Francis J. Jaworski

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97(d)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97(b) and 1.98, Applicant for the above-identified application hereby submits a legible copy of the following relevant art along with the form PTO-1449 which contains the information as required by 37 CFR 1.98(b):

A. Japanese Patent Application Laid-Open (Kokai) No. 2000-300555 published on October 31, 2000 by the European Patent Office; and

B. <http://web.archive.org/web/20010914030153/http://www.clevelandclinic.org/cancer/general/glossary/1.htm>.

The above-listed prior arts are cited in the Office Action which was issued on August 16, 2005 by the European Patent Office for European Patent Application No. EP 03 023 959 which is a counterpart application to the above-identified U.S. application. A copy of the Office Action is enclosed.

The prior art A is in Japanese, and the English translation of this prior art is not available at this time to the undersigned. However, an English language abstract is attached to this non-English prior art. Accordingly, pursuant to MPEP Section 609, the requirement for a concise explanation of the relevance is satisfied, and an English concise explanation of the prior art A is omitted herein.

10/28/2005 HTECKLU1 00000019 10691070

01 FC:1806

180.00 OP

Pursuant to CFR 1.97(d)(1), the required statement as shown below:

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

In addition, pursuant to 37 CFR 1.97 (d)(2), our check for \$180.00 to cover the required fee set forth in 37 CFR 1.17(p) is enclosed.

In view of the above, it is therefore respectfully requested that the Patent Office make a record of these relevant arts and consider them.

Respectfully submitted,

KODA & ANDROLIA

By: 

William L. Androlia

Reg. No. 27,177

2029 Century Park East
Suite 1140
Los Angeles, CA 90067-2983
Tel: (310) 277-1391
Fax: (310) 277-4118

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:


Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450, on

October 24, 2005

Date of Deposit

William L. Androlia

Name

 10/24/2005

Signature

Date



FORM PTO-1449			Docket Number (Optional) 29A 3485		Application Number 10/691,070	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Masaru Murashita			
(Use several sheets if necessary)			Filing Date 10/22/2003		Group Art Unit 3737	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	JP 2000-300555	10/31/2000	Japan	A61B	8/00	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	http://web.archive.org/web/20010914030153/http://www.clevelandclinic.org/cancer/general/glossary/l.htm					
EXAMINER		DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.						